JP2022062358A - 血管攣縮抑制剤、血管攣縮予防剤、並びに血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 - Google Patents
血管攣縮抑制剤、血管攣縮予防剤、並びに血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 Download PDFInfo
- Publication number
- JP2022062358A JP2022062358A JP2020170315A JP2020170315A JP2022062358A JP 2022062358 A JP2022062358 A JP 2022062358A JP 2020170315 A JP2020170315 A JP 2020170315A JP 2020170315 A JP2020170315 A JP 2020170315A JP 2022062358 A JP2022062358 A JP 2022062358A
- Authority
- JP
- Japan
- Prior art keywords
- vasospasm
- compound
- oral composition
- inhibitor
- morus alba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010047163 Vasospasm Diseases 0.000 title claims abstract description 77
- 239000003112 inhibitor Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000003449 preventive effect Effects 0.000 title claims abstract description 6
- 230000002265 prevention Effects 0.000 title abstract description 6
- 230000005764 inhibitory process Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 240000000249 Morus alba Species 0.000 claims description 65
- 235000008708 Morus alba Nutrition 0.000 claims description 65
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 60
- 235000011990 fisetin Nutrition 0.000 claims description 30
- 239000000284 extract Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 abstract description 49
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 208000005392 Spasm Diseases 0.000 abstract 1
- 230000008602 contraction Effects 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 21
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 21
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 235000009498 luteolin Nutrition 0.000 description 11
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 11
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 10
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 10
- 235000005875 quercetin Nutrition 0.000 description 10
- 229960001285 quercetin Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- JLVSPVFPBBFMBE-HXSWCURESA-O sphingosylphosphocholine acid Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H]([NH3+])COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-O 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- -1 alkali metal salts Chemical class 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000002196 fr. b Anatomy 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000019512 sardine Nutrition 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000043827 human Smooth muscle Human genes 0.000 description 2
- 108700038605 human Smooth muscle Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 102000000568 rho-Associated Kinases Human genes 0.000 description 2
- 108010041788 rho-Associated Kinases Proteins 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 241000522213 Dichilus lebeckioides Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 240000009253 Morus australis Species 0.000 description 1
- 235000006723 Morus australis Nutrition 0.000 description 1
- 241000917689 Morus mesozygia Species 0.000 description 1
- 101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 1
- 101710107065 Myosin regulatory light polypeptide 9 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004710 electron pair approximation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002540 product ion scan Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
こととしてもよい。
フィセチンである、
こととしてもよい。
前記化合物をクワ科クワ属に属する植物の抽出物として含有する、
こととしてもよい。
本実施の形態に係る血管攣縮抑制剤は、次の式(1)に示される構造を有する化合物又はその塩(以下、単に“化合物X”とする)を有効成分として含有する。式(1)におけるR1及びR2は、それぞれ独立して水素原子又は水酸基である。
桑葉(ヤマグワ:Morus australis)試料30mgを70%エタノールにより抽出し、濃縮乾固した乾固物をHEPES緩衝液(HK-3320、倉敷紡績社製)で溶解し4mg/mL桑試料抽出液とした。1.0×105細胞/mLの正常ヒト冠状動脈平滑筋細胞の細胞懸濁液100μLと増殖培地(正常ヒト平滑筋細胞用増殖培地KS-2170S、倉敷紡績社製)200μLとを24ウェルプレートの各ウェルに播種し、37℃、CO2濃度5%に設定したCO2インキュベーターで培養した。なお、以下での細胞の培養は37℃、CO2濃度5%に設定したCO2インキュベーターで培養した。
図1は、細胞表面積の相対値の経時変化を示す。桑試料抽出液に暴露しなかった細胞は、異常収縮により細胞表面積が低下したが、桑試料抽出液に暴露した場合、細胞表面積がほとんど低下しなかった。
1.0×105細胞/mLの正常ヒト冠状動脈平滑筋細胞の細胞懸濁液100μLと増殖培地200μLとを24ウェルプレートの各ウェルに播種し、培養した。抑制効果の評価では、桑試料抽出液を添加せずに増殖培地での前培養を行った。培養後、上清を全て除去し、基礎培地200μL/ウェルを添加後、12時間以上培養した。プレートをインキュベーターから取り出し、6μM Fluo3-AMを200μL/ウェル添加(最終濃度:3μM/ウェル)後、1時間培養した。さらに、上清を200μL/ウェルずつ除去し、2mM CaCl2を200μL/ウェル添加し、細胞の培養と同じ条件下で30分間反応させた。60μM SPCを200μL/ウェル(最終濃度:30μM/ウェル)添加による異常収縮誘発直後に、4mg/mL桑試料抽出液を100μL/ウェル添加し、37℃、CO2濃度5%に設定したCO2インキュベーターで反応させた。反応後、プレートをインキュベーターから取り出し、異常収縮の形態観察を行った。異常収縮の形態観察では、桑試料抽出液添加後約1分に加え、添加後5分及び10分の画像を取得し、試験例1と同様に評価した。
図2に示された細胞表面積の相対値の経時変化によれば、異常収縮誘発後に桑試料抽出液に暴露しても、細胞表面積の低下が抑制された。
ゲルろ過クロマトグラフィーは、Prepacked Disposable PD-10 Column(17085101、グローバルライフサイエンステクノロジーズジャパン社製)に超純水10mL以上を通液し、コンディショニング後、使用した。試料は、桑葉を70%エタノールにより抽出し濃縮乾固した乾固物を乾固物重量が20mg/mLになるように超純水で溶解し、フィルターろ過後、使用した。コンディショニング完了後、20mg/mL桑試料抽出液1mLと超純水2mLを通液し、素通り画分を画分1として回収した。その後、フィルターを枯らさないように超純水を3mL通液し、素通り画分を画分2として回収し、同様の操作を画分8まで繰り返した。得られた素通り画分は、-20℃で凍結し、凍結乾燥後、画分6~8は収量が少なかったため混合し、画分6とした。また画分1は、カラムの特性上、分子量5000以上の物質であることから、経口摂取による機能性が期待されないため除外した。得られた画分2~6の乾固物は、HEPES緩衝液(HK-3320、倉敷紡績社製)にて0.4mg/mLになるように溶解し、0.45μmフィルターろ過後、評価試料とした。評価試料の最終濃度が0.1mg/mLとなるようにHEPES緩衝液で調製し、各画分による異常収縮予防効果を試験例1と同様に確認した。
図3に示すように、画分6の異常収縮予防効果が最も高かった。画分6から異常収縮を予防又は抑制する物質を以下で同定した。
HPLCでの分取は、LC-2000(日本分光社製)を用い、320nmの吸収スペクトルを検出した。分離カラムは、TSKgel ODS-100Z 5μm(4.6mmI.D.×15.0cm、東ソー社製)を用い、カラムオーブン温度は40℃とし、流速は1mL/分でサンプルは100μL注入した。分離は、0.1vol%トリフルオロ酢酸(202-10733、富士フイルム和光純薬社製)、アセトニトリル(純度99.9%、34888-2.5L、シグマアルドリッチジャパン社製)で、アセトニトリルを(1)0-10分 10%、(2)10-20分 100%まで上昇、(3)20-30分 100%に勾配をかけ分取した。保持時間0-10分、10-20分及び20-30分の画分をそれぞれA、B及びCとした(図4参照)。得られた溶液は、エバポレーターにより減圧濃縮した後、-20℃で凍結し、凍結乾燥し得られた乾固物を評価試料とした。評価試料について、各画分による異常収縮予防効果を試験例1と同様に確認した。
図5に示すように画分Bの異常収縮予防効果が最も高かった。画分Bに含まれる活性成分を以下のようにLC/MSで同定した。
活性成分の同定は、HPLC Shimadzu system LC20(島津製作所製)を装備したQTRAP LC-MS/MS 3200システム(エービー・サイエックス社製)を用い、ポジティブモードで検出した。以下の条件でAn information dependent acquisition(IDA)によるenhanced mass scan(EMS)でサーベイスキャンを行い、次にenhanced resolution(ER)で質量誤差の補正や、同位体分布を確認した後、enhanced product ion(EPI) scanでプロダクトイオンスキャンを行ってフラグメント情報を取得した。
図6(A)に示されたUVスペクトルにおける保持時間10.12分のピークを質量分析法(MS)で測定することで得られた分子量関連イオンのピークから分子量286.9を確認した。化合物を検索し、分子式を推定し、さらにMS/MS測定によって検出された図6(B)に示すプロダクトイオンスペクトルから画分Bに含まれる活性成分としてフィセチンを同定した。
フィセチンのHPLCによる定量では、LC-2000(ポンプ:PU-2080、検出器:UV-2070、オートサンプラー:AS-4050、カラムオーブン:CO-4060、日本分光社製)を用い、320nmの吸収スペクトルを検出した。分離カラムは、TSKgel ODS-100Z 5μm(4.6mmI.D.×15.0cm、東ソー社製)を用いた。カラムオーブン温度は40℃とし、流速は1mL/分で、サンプルは10μL注入した。分離は、0.1vol%トリフルオロ酢酸(202-10733、富士フイルム和光純薬社製)、メタノール(純度99.8%、21929-23、ナカライテスク社製)で、1:1のイソクラティックで行った。
図7にHPLCの結果を示す。保持時間5分のピークがフィセチンに対応する。なお、本実施例で使用した桑葉(ヤマグワ)では、ルテオリンは検出されなかった。図8に示すように、定量の結果、桑葉中のフィセチンの含有量は0.6mg/g乾燥粉末であった。一方、果実にはフィセチンが含まれていなかった。
試験例1における桑試料抽出液を市販のフィセチン(東京化成工業社製)に代えて、フィセチンの異常収縮予防効果をさらに評価した。1、10又は100μMの濃度のフィセチンに細胞を暴露し、10分後の細胞の表面積を算出した。
図9に示すように、フィセチンによって細胞表面積はほとんど低下しなかった。図10は、異常収縮誘発前の細胞の画像及び誘発後10分の細胞の画像を示す。細胞の所定の部分の長さを測定し、細胞の異常収縮の程度として長さの変化率を評価したところ、対照は変化率が29.6%であったのに対し、フィセチンに暴露した細胞では、変化率が2.3%でほとんど変化していなかった。
桑葉に含まれるフィセチン(東京化成工業社製)、ルテオリン(Cayman Chemical社製)及びケルセチン(Cayman Chemical社製)について試験例1と同様に異常収縮予防効果を評価した。5μMの濃度のフィセチン、ルテオリン及びケルセチンに細胞を暴露し、5分後の細胞表面積を算出した。
図11は、フィセチン、ルテオリン及びケルセチンの各構造と、フィセチンの異常収縮予防効果を100とした場合のルテオリン及びケルセチンの相対的な異常収縮予防効果を示す。フィセチン、ルテオリン及びケルセチンのいずれにも異常収縮予防効果を確認した。フィセチンとの違いがA環5位に水酸基がある点のみであるケルセチンの異常収縮予防効果が、C環3位に水酸基がなくA環5位に水酸基があるルテオリンよりも高かった。ケルセチン及びルテオリンは桑(Morus alba)に含まれることが知られている。
Claims (6)
- 前記式(1)におけるR1は、水酸基である、
請求項1に記載の血管攣縮剤。 - 前記化合物は、
フィセチンである、
請求項1又は2に記載の血管攣縮剤。 - 前記化合物をクワ科クワ属に属する植物の抽出物として含有する、
請求項1から3のいずれか一項に記載の血管攣縮抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020170315A JP7401863B2 (ja) | 2020-10-08 | 2020-10-08 | 血管攣縮抑制剤、血管攣縮予防剤、血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020170315A JP7401863B2 (ja) | 2020-10-08 | 2020-10-08 | 血管攣縮抑制剤、血管攣縮予防剤、血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022062358A true JP2022062358A (ja) | 2022-04-20 |
JP2022062358A5 JP2022062358A5 (ja) | 2023-08-04 |
JP7401863B2 JP7401863B2 (ja) | 2023-12-20 |
Family
ID=81211088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020170315A Active JP7401863B2 (ja) | 2020-10-08 | 2020-10-08 | 血管攣縮抑制剤、血管攣縮予防剤、血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7401863B2 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2002524522A (ja) * | 1998-09-15 | 2002-08-06 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 高血中脂質濃度に因る疾患の予防または治療のための、ルチンおよびケルセチンを含む組成物 |
JP2003527434A (ja) * | 2000-03-22 | 2003-09-16 | エヌ・ヴイ・ヌートリシア | 虚血/再潅流又は酸化的ストレスに起因する損傷の治療に適した組成物 |
JP2010504370A (ja) * | 2006-09-25 | 2010-02-12 | ベンズ ラブ シーオー エルティーディー | 抗アレルギー性鼻炎作用、抗アトピー性皮膚炎作用及び抗喘息活性を示す複合生薬抽出物からなる組成物 |
JP2012171951A (ja) * | 2011-02-24 | 2012-09-10 | Kao Corp | ミネラロコルチコイド受容体阻害剤 |
JP2016079117A (ja) * | 2014-10-14 | 2016-05-16 | 国立大学法人山口大学 | 血管攣縮抑制剤 |
WO2016132483A1 (ja) * | 2015-02-18 | 2016-08-25 | 学校法人福岡大学 | ヒトキマーゼ阻害剤及びヒトキマーゼの活性が関与する疾患の予防治療用薬剤 |
-
2020
- 2020-10-08 JP JP2020170315A patent/JP7401863B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002524522A (ja) * | 1998-09-15 | 2002-08-06 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 高血中脂質濃度に因る疾患の予防または治療のための、ルチンおよびケルセチンを含む組成物 |
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2003527434A (ja) * | 2000-03-22 | 2003-09-16 | エヌ・ヴイ・ヌートリシア | 虚血/再潅流又は酸化的ストレスに起因する損傷の治療に適した組成物 |
JP2010504370A (ja) * | 2006-09-25 | 2010-02-12 | ベンズ ラブ シーオー エルティーディー | 抗アレルギー性鼻炎作用、抗アトピー性皮膚炎作用及び抗喘息活性を示す複合生薬抽出物からなる組成物 |
JP2012171951A (ja) * | 2011-02-24 | 2012-09-10 | Kao Corp | ミネラロコルチコイド受容体阻害剤 |
JP2016079117A (ja) * | 2014-10-14 | 2016-05-16 | 国立大学法人山口大学 | 血管攣縮抑制剤 |
WO2016132483A1 (ja) * | 2015-02-18 | 2016-08-25 | 学校法人福岡大学 | ヒトキマーゼ阻害剤及びヒトキマーゼの活性が関与する疾患の予防治療用薬剤 |
Non-Patent Citations (3)
Title |
---|
CHEN-HUI ZHOU ET AL.: ""Fisetin alleviates early brain injury following experimental subarachnoid hemorrhage in rats possib", BRAIN RESEARCH, vol. 1629, JPN6023036283, 2015, pages 250 - 259, ISSN: 0005144118 * |
GUL SANSER ET AL.: ""Neuroprotective effects of quercetin on cerebral vasospasm following experimental subarachnoid haem", TURKISH JOURNAL OF MEDICAL SCIENCES, vol. 50, JPN6023036284, 23 February 2020 (2020-02-23), pages 1106 - 1110, ISSN: 0005144119 * |
YU-SHU DONG ET AL.: ""Protective Effect of Quercetin against Oxidative Stress and Brain Edema in an Experimental Rat Mode", INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol. 11, JPN6023036285, 2014, pages 282 - 290, ISSN: 0005144120 * |
Also Published As
Publication number | Publication date |
---|---|
JP7401863B2 (ja) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100544856B1 (ko) | 조류 유래의 생리활성물질을 이용한 의약, 식품 또는 음료 | |
JP5793739B2 (ja) | 金銀花抽出物を含む逆流性食道炎治療または予防用薬学組成物 | |
KR101621856B1 (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
KR101406201B1 (ko) | 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물 | |
US20160228402A1 (en) | Composition containing lignan compound as active ingredient for preventing or treating cancer | |
KR100683966B1 (ko) | 사가크롬산 유도체를 함유하는 안지오텐신 전환효소 활성억제제 및 이의 약학적 조성물 | |
KR102057745B1 (ko) | 탈람노실 악테오사이드 함유 올리브 추출물 | |
KR20240020729A (ko) | 구멍쇠미역 추출물로부터 분리된 화합물을 포함하는 근육질환의 예방 또는 치료용 조성물 | |
JP6910639B2 (ja) | アンジオテンシン変換酵素阻害剤、組成物およびその製造方法 | |
JP7401863B2 (ja) | 血管攣縮抑制剤、血管攣縮予防剤、血管攣縮予防用経口組成物及び血管攣縮抑制用経口組成物 | |
KR101039145B1 (ko) | 부들 추출물을 포함하는 순환기 질환의 예방 및 치료용 조성물 | |
KR20110057010A (ko) | 폴리페놀성 화합물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 | |
KR102348782B1 (ko) | 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
KR102566433B1 (ko) | 커피 실버스킨 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 근육질환의 예방 또는 치료용 조성물 | |
RU2713906C2 (ru) | Новое соединение (ks513), выделенное из pseudolysimachion rotundum var. subintegrum, композиция, содержащая указанное соединение в качестве активного ингредиента, для предотвращения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких и их применение | |
KR100999872B1 (ko) | 홍경천 추출물, 홍경천 분획물, 이로부터 분리한플라보노이드계 화합물, 이의 유도체 화합물 또는 이의약학적으로 허용 가능한 염을 유효성분으로 함유하는바이러스 질환의 예방 및 치료용 약학적 조성물 | |
JP5635932B2 (ja) | プロセシンググルコシダーゼ阻害剤 | |
KR20200069616A (ko) | 올벚나무를 포함하는 항염증용 조성물 | |
KR102226992B1 (ko) | 고량강 유래 다이아릴헵타노이드 화합물을 유효성분으로 포함하는 뉴라미니데이즈 활성 억제용 조성물 | |
KR20190099961A (ko) | 아젤라산을 유효성분으로 포함하는 미토콘드리아 합성을 통한 근육강화 촉진용 조성물 | |
KR20190142672A (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
KR101189822B1 (ko) | 쿠마린계 화합물을 포함하는 뉴라미니데이즈 활성의 억제용 조성물 및 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물 | |
KR102069125B1 (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
KR101937435B1 (ko) | 글리시리직애씨드 및 이의 용도 | |
WO2011068386A2 (ko) | 캄페라이드 화합물을 유효성분으로 함유하는 항암용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230726 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231129 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7401863 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |